Multivalent PcrV-Binding Antibodies for Pseudomonas aeruginosa Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Pseudomonas aeruginosa infections, particularly those involving the Type III Secretion System, face challenges due to biofilm formation, antibiotic resistance, and the limited efficacy of existing antibiotics, leading to a shortage of effective therapeutic options, especially for chronic and nosocomial infections.
Innovation Solution
Development of multivalent polypeptides comprising two or more immunoglobulin single variable domains that specifically bind to the PcrV protein, offering improved neutralization efficacy and stability compared to monovalent antibodies, with biparatopic or triparatopic configurations that can inhibit the Type III Secretion System effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monovalent antibodies are used to bind PcrV, then binding specificity is achieved, but neutralization efficacy is insufficient
Solution Approach 1:
The patent combines multiple monovalent antibody domains (at least two, preferably three) into a single multivalent polypeptide structure that binds to multiple epitopes on the PcrV protein simultaneously. This merging of binding units achieves enhanced neutralization efficacy (100% efficacy in cytotoxicity assays) compared to monovalent antibodies, while maintaining a unified polypeptide structure rather than requiring separate antibody molecules.
Solution Approach 2:
The multivalent polypeptide is segmented into multiple immunoglobulin single variable domains (e.g., VH1, VH2, VH3), each responsible for binding to a specific epitope on the PcrV protein. This segmentation allows the single polypeptide to engage multiple binding sites simultaneously, achieving multiparatopic binding that enhances neutralization while distributing the binding function across discrete structural modules.
2Reliability
If conventional antibiotics are used to treat Pseudomonas aeruginosa infections, then bacterial growth inhibition is achieved, but resistance development occurs
Solution Approach 1:
The patent replaces the chemical mechanism of antibiotics (which target bacterial cell walls, proteins, or DNA and promote resistance through selective pressure) with a biological mechanism using engineered polypeptides that bind to specific protein epitopes on the bacterial surface. This substitution of the therapeutic mechanism avoids the development of resistance by not creating selective pressure for resistant mutants, while maintaining high therapeutic efficacy through direct neutralization of the Type III Secretion System.
3Reliability
If biofilm-forming Pseudomonas aeruginosa is treated with antibiotics, then bacterial killing is attempted, but treatment efficacy is reduced
Solution Approach 1:
The multivalent polypeptide performs preliminary neutralization by binding to and blocking the PcrV protein on the bacterial surface before the Type III Secretion System can inject toxins into host cells. This preliminary action at the surface level prevents the harmful effects of biofilm-mediated toxin delivery, achieving 100% efficacy in cytotoxicity assays by neutralizing the secretion system's function rather than attempting to kill the bacteria themselves.
4Reliability
If chronic Pseudomonas aeruginosa infections are treated with existing therapies, then infection control is attempted, but eradication is impossible
Solution Approach 1:
The multivalent polypeptide exhibits universal binding capability across different strains of Pseudomonas aeruginosa by targeting conserved epitopes on the PcrV protein, which is essential for the Type III Secretion System function. This universal mechanism, combined with the ability to neutralize the secretion system's toxin injection capability, provides effective control and potential eradication of chronic infections by addressing the common functional requirement of all strains rather than targeting variable surface characteristics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multivalent polypeptides demonstrate 100% efficacy in cytotoxicity assays and maintain potency even in the presence of elastase or neutrophil elastase, providing a promising non-antibiotic solution for Pseudomonas aeruginosa infections with enhanced stability and reduced resistance concerns.
Implementation Method 1
multivalent polypeptides comprising two or more immunoglobulin single variable domains that specifically bind to the PcrV protein
Implementation Method 2
neutralize PcrV and neutralize P. aeruginosa
Data Source
AI summary
Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P. aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.